Article Figures & Data
Figures
- Figure 1
Summary of NY-ESO-1 and LAGE-1 expression in TCCs as determined by IHC and RT-PCR
- Figure 2
Recurrence-free survival in patients whose tumors expressed antigen (NY-ESO-1 or LAGE-1) versus patients whose tumors did not express antigen
- Figure 3
Antibodies to NY-ESO-1 in patient UC-098 at various time points. Antibodies to NY-ESO-1 at 8 , 10 and 22 months after cystectomy are shown, as compared to a known positive control and negative control.
- Figure 4
Expression of NY-ESO-1 in patient UC-098 with invasive transitional cell carcinoma. Homogeneous expression of NY-ESO-1 in urinary bladder was detected with monoclonal antibody ES121.
- Figure 5
Mapping of the epitope within region 80-109 of NY-ESO-1. ELISPOT assay with CD8+ T cells from patient UC-098 presensitized with NY-ESO-1 peptide 80-109 and tested against histocompatible B-EBV targets pulsed with peptides at 10 µM (A and B) or at various concentrations (C).
- Figure 6
Identification of the restriction element responsible for the observed T cell response. ELISPOT assay with CD8+ T cells from patient UC-098 presensitized with NY-ESO-1 peptide 80-109 and tested against partially histocompatible B-EBV targets pulsed or not with NY-ESO-1 peptide 94-102. The complete class I haplotype from UC-098 is indicated on top, matching target alleles are shown in bold and italic print.
- Figure 7
NY-ESO-1 peptide 94-102 is naturally processed from the full-length protein in antigen-presenting cells. ELISPOT assay with CD8+ T cells from patient UC-098 presensitized with NY-ESO-1 peptide 80-109 and tested against histocompatible B-EBV targets pulsed with NY-ESO-1 peptides, or infected with vaccinia virus recombinant for NY-ESO-1 or wild-type (A); or tested against melanoma cell lines pulsed or not with NY-ESO-1 peptide 94-102 (B).
Tables
- Table 1
RT-PCR and IHC results from high-grade TCCs.
Patient Number Pathology IHC RT-PCR NY-ESO-1 NY-ESO-1 LAGE-1 UC014 TaG1 + CIS not tested - + UC032 T2 + CIS not tested - + UC033 T1 - - - UC037 T4 + + + UC040 T1 +CIS - - - UC041 T2 - - - UC060 T2 - + + UC061 T2 + CIS + + + UC063 CIS not tested + - UC067 T3 - + + UC070 T1 + CIS - - - UC081 T2 - - - UC095 CIS not tested - - UC099 Ta-high grade - + - UC101 T2 + CIS - - - UC106 Ta-high grade - + + UC113 CIS - + + UC114 T1 - + - UC117 Ta-high grade - - + UC121 Ta-high grade not tested - - UC124 T1 - + - UC128 T2 - - - UC131 CIS - - - UC139 T2 not tested - - UC141 T1 not tested - - UC143 T2 + CIS - - + UC144 T2 - - - UC146 T2 - - + UC148 T1 - + + UC149 T2 - - - UC150 T1 - - + UC155 CIS not tested - - UC160 T2 + - - UC161 T2 - - - UC164 T3 - - + UC165 CIS not tested - - UC166 T3 + CIS - - - UC169 T2 + CIS not tested - - UC170 T3 + CIS + + + UC201 T3 + CIS + + + UC202 T3 + + - UC203 T3 + CIS - - - UC204 T3 - + + - Table 2
Characteristics of the patients included in the statistical analysis.
Pathology N (%) CIS 12 (17) T1 11 (16) T1 + CIS 3 (4) T2 9 (13) T2 + CIS 4 (6) T3 7 (10) T3 + CIS 7 (10) T4 3 (4) TaG1 + CIS 2 (3) TaG3 10 (15) TaG3 + CIS 1 (2) Diagnosis Dates Starting 6/97 Ending 11/02 Survival Status N (%) Alive 61 (88) Dead 8 (12) Antigen Results N Positive (for at least 1) 33 Negative 36 - Table 3
Summary of recurrence-free survival (RFS) for 69 patients with high-grade TCC.
RFS All Patients Ag Negative Patients Ag Positive Patients Median RFS (95% CI) 24.4 mo (15.8, 70.2) 24.4 mo (17.9, 70.2) Not reached One-year RFS (95% CI) 68% (57, 79) 69% (54, 85) 67% (50, 83) Two-year RFS (95% CI) 51% (38, 64) 51% (33, 69) 52% (34, 70)
Volume 3, Issue 1
